Key Points
- Insider sale: Director Dennis Cho sold 5,000 shares on Feb. 11 at an average price of $49.93 for $249,650, reducing his direct stake to 138,581 shares (a 3.48% decline).
- Quarterly results: Twist reported Q results with EPS of -$0.50 (missing estimates by $0.02) while revenue of $103.7 million beat expectations and rose 16.9% year-over-year, though the company remains unprofitable with negative ROE and net margin.
- Stock and analyst backdrop: TWST shares were up ~3.0%, trade near a one-year high of $51.00 with a $3.01 billion market cap, and carry a consensus "Moderate Buy" from analysts with an average price target of $45.88.
Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) insider Dennis Cho sold 5,000 shares of the firm's stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $49.93, for a total transaction of $249,650.00. Following the sale, the insider directly owned 138,581 shares in the company, valued at $6,919,349.33. This represents a 3.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Dennis Cho also recently made the following trade(s):
- On Tuesday, February 3rd, Dennis Cho sold 1,099 shares of Twist Bioscience stock. The shares were sold at an average price of $46.58, for a total transaction of $51,191.42.
- On Monday, December 22nd, Dennis Cho sold 324 shares of Twist Bioscience stock. The stock was sold at an average price of $34.56, for a total transaction of $11,197.44.
Twist Bioscience Stock Up 3.0%
TWST stock opened at $49.11 on Friday. The company has a 50 day moving average price of $38.63 and a two-hundred day moving average price of $32.48. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.37 and a current ratio of 3.78. The stock has a market capitalization of $3.01 billion, a P/E ratio of -38.37 and a beta of 2.24. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $51.00.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The business had revenue of $103.70 million for the quarter, compared to analyst estimates of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The business's revenue for the quarter was up 16.9% compared to the same quarter last year. As a group, sell-side analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current year.
Wall Street Analyst Weigh In
TWST has been the subject of a number of research analyst reports. Robert W. Baird set a $50.00 price objective on shares of Twist Bioscience in a research note on Tuesday, February 3rd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Twist Bioscience in a research report on Monday, December 29th. Stephens initiated coverage on shares of Twist Bioscience in a research note on Monday, November 3rd. They set an "overweight" rating and a $41.00 price target on the stock. Barclays boosted their price objective on shares of Twist Bioscience from $39.00 to $50.00 and gave the company an "overweight" rating in a research note on Tuesday, February 3rd. Finally, TD Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, Twist Bioscience currently has a consensus rating of "Moderate Buy" and an average price target of $45.88.
View Our Latest Analysis on TWST
Institutional Investors Weigh In On Twist Bioscience
Large investors have recently made changes to their positions in the business. Quarry LP acquired a new position in shares of Twist Bioscience during the 3rd quarter valued at $28,000. Strategic Advocates LLC raised its position in Twist Bioscience by 562.7% in the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company's stock valued at $34,000 after purchasing an additional 906 shares during the period. Smartleaf Asset Management LLC lifted its stake in shares of Twist Bioscience by 70.6% during the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company's stock worth $29,000 after purchasing an additional 442 shares in the last quarter. SBI Securities Co. Ltd. boosted its position in shares of Twist Bioscience by 68.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company's stock worth $44,000 after buying an additional 571 shares during the period. Finally, Leonteq Securities AG acquired a new stake in shares of Twist Bioscience in the fourth quarter valued at about $48,000.
About Twist Bioscience
(
Get Free Report)
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
